title: Use of topical bevacizumab for conjunctival intraepithelial neoplasia.
abstract: OBJECTIVE
  To report our experience in the treatment of intraepithelial neoplasia of the conjunctiva using topical bevacizumab.
  
  
  METHODS
  Ten eyes of 10 patients with conjunctival neoplasia received 25 mg/mL bevacizumab topically. Changes in the lesions were documented weekly using digital photography. After topical treatment, excisional biopsy was performed.
  
  
  RESULTS
  The mean age of the patients was 60.5 ± 12 (33-77) years. The mean duration of topical treatment was 7.8 ± 1.3 (5-14) weeks. The size and vascularity of the tumors reduced weekly. All patients underwent excisional biopsy, cryotherapy, and amnion membrane transplantation. The histopathologic diagnosis of the lesions was carcinoma in situ. No recurrence was observed during the follow-up of patients for 6 months.
  
  
  CONCLUSIONS
  Topical bevacizumab is an effective treatment to reduce the tumor size before surgery and may be a good alternative for adjuvant therapy of conjunctival neoplasms.
authors.affiliation: *Faculty of Medicine, Department of Ophthalmology, Çukurova University, Adana, Turkey; and †Department of Ophthalmology, Adana Numune Training and Research Hospital, Adana, Turkey.
authors.forename: Altan A
authors.initials: AA
authors.lastname: Özcan
authors.forename: Emine
authors.initials: E
authors.lastname: Çiloğlu
authors.forename: Ebru
authors.initials: E
authors.lastname: Esen
authors.forename: Göksu H
authors.initials: GH
authors.lastname: Şimdivar
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D001706:Biopsy; D002278:Carcinoma in Situ / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D003230:Conjunctival Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D017679:Cryotherapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000473:pathology; D009883:Ophthalmic Solutions; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D009883:Ophthalmic Solutions; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab